| Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein, AN Loes, SK Hilton, ... Cell host & microbe 29 (1), 44-57. e9, 2021 | 1121 | 2021 |
| Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays KHD Crawford, R Eguia, AS Dingens, AN Loes, KD Malone, CR Wolf, ... Viruses 12 (5), 513, 2020 | 777 | 2020 |
| Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection KHD Crawford, AS Dingens, R Eguia, CR Wolf, N Wilcox, JK Logue, ... The Journal of infectious diseases 223 (2), 197-205, 2021 | 317 | 2021 |
| A human coronavirus evolves antigenically to escape antibody immunity RT Eguia, KHD Crawford, T Stevens-Ayers, L Kelnhofer-Millevolte, ... PLoS pathogens 17 (4), e1009453, 2021 | 214 | 2021 |
| Mapping person-to-person variation in viral mutations that escape polyclonal serum targeting influenza hemagglutinin JM Lee, R Eguia, SJ Zost, S Choudhary, PC Wilson, T Bedford, ... Elife 8, e49324, 2019 | 93 | 2019 |
| Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak AS Dingens, KHD Crawford, A Adler, SL Steele, K Lacombe, R Eguia, ... Nature communications 11 (1), 4378, 2020 | 71 | 2020 |
| A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy AJ Greaney, TN Starr, RT Eguia, AN Loes, K Khan, F Karim, S Cele, ... PLoS pathogens 18 (2), e1010248, 2022 | 61 | 2022 |
| Comprehensive mapping of adaptation of the avian influenza polymerase protein PB2 to humans YQS Soh, LH Moncla, R Eguia, T Bedford, JD Bloom Elife 8, e45079, 2019 | 54 | 2019 |
| Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein MA Tortorici, AC Walls, A Joshi, YJ Park, RT Eguia, MC Miranda, E Kepl, ... Cell 185 (13), 2279-2291. e17, 2022 | 51 | 2022 |
| Receptor-binding domain (RBD) antibodies contribute more to SARS-CoV-2 neutralization when target cells express high levels of ACE2 AG Farrell, B Dadonaite, AJ Greaney, R Eguia, AN Loes, NM Franko, ... Viruses 14 (9), 2061, 2022 | 26 | 2022 |
| The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes AJ Greaney, RT Eguia, TN Starr, K Khan, N Franko, JK Logue, SM Lord, ... PLoS Pathogens 18 (6), e1010592, 2022 | 16 | 2022 |
| Comprehensive profiling of mutations to influenza virus PB2 that confer resistance to the cap-binding inhibitor pimodivir YQS Soh, KD Malone, RT Eguia, JD Bloom Viruses 13 (7), 1196, 2021 | 14 | 2021 |
| Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin FC Welsh, RT Eguia, JM Lee, HK Haddox, J Galloway, NVV Chau, ... Cell Host & Microbe 32 (8), 1397-1411. e11, 2024 | 6 | 2024 |
| Pseudotyping lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays KHD Crawford, R Eguia, AS Dingens, AN Loes, JD Bloom | 3 | 2020 |
| Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses 12 (5): 513 KHD Crawford, R Eguia, AS Dingens, AN Loes, KD Malone, CR Wolf, ... | 3 | 2020 |
| Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. bioRxiv, 2020.09. 10.292078 AJ Greaney, TN Starr, P Gilchuk, SJ Zost, E Binshtein, AN Loes, SK Hilton, ... | 2 | 2020 |
| Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak. Nat Commun 11: 4378 AS Dingens, KHD Crawford, A Adler, SL Steele, K Lacombe, R Eguia, ... | 2 | 2020 |
| 1 2 3 4 5 6 7 8 9Lead contact* Correspondence: https://doi. org MA Tortorici, AC Walls, A Joshi, YJ Park, RT Eguia, MC Miranda, E Kepl, ... CELL 185 (13), 2279-+, 2022 | | 2022 |
